PPAR Research

Review Article

PPAR- in the Cardiovascular System

Table 1

Cardiovascular phenotypes in gain and loss of PPAR- function.
CHMIBPCADAS
TZDs Agonism Gain of function [30–33, 47] [34] [17, 49, 50] [87–91]
Pro12Ala Human mutation Loss of function [57] [58]
Pro467Leu Human mutation Loss of function [59, 60]
Val290Met Human mutation Loss of function [60]
Phe388Leu Human mutation Loss of function [61]
Arg425Cys Human mutation Loss of function [62]
C161T Human mutation Loss of function [63]
Pro467Leu Mouse mutation Loss of function [69]
Leu466Ala Mouse mutation Loss of function [70]
Generalized KO Transgenic mouse Loss of function [71] [71]
Cardiac KO Transgenic mouse Loss of function [47]
Endothelial KO Transgenic mouse Loss of function [75]
Collecting duct KO Transgenic mouse Loss of function [40, 41]
TZDs: thiazolidinediones; KO: knockout; CH: cardiac hypertrophy;
MI: myocardial infarction; BP: blood pressure; CAD: coronary artery disease; AS: atherosclerosis
*: in animals only; **: rosiglitazone only
Numbers in square brackets are the reference numbers.